Sienna Biopharmaceuticals (SNNAQ) Ratios
Sienna Biopharmaceuticals Ratios
SNNAQ's free cash flow for Q3 2019 was $-17.84M. For the 2019 fiscal year, SNNAQ's free cash flow was increased by $0.00 and operating cash flow was $-17.84M. See a summary of the company’s cash flow.
| Ratios | Dec 18 | Dec 17 |
|---|---|---|
| Liquidity Ratios | ||
| Current Ratio | 2.07 | 9.39 |
| Quick Ratio | 2.07 | 9.39 |
| Cash Ratio | 1.99 | 9.04 |
| Solvency Ratio | -0.91 | -1.10 |
| Operating Cash Flow Ratio | -2.53 | -4.99 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 |
| Net Current Asset Value | $ -30.31M | $ 31.70M |
| Leverage Ratios | ||
| Debt-to-Assets Ratio | 0.28 | 0.00 |
| Debt-to-Equity Ratio | 0.19 | 0.00 |
| Debt-to-Capital Ratio | 0.16 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.16 | 0.00 |
| Financial Leverage Ratio | 0.67 | 1.59 |
| Debt Service Coverage Ratio | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 |
| Debt to Market Cap | 0.63 | 0.00 |
| Interest Debt Per Share | 1.47 | 0.00 |
| Net Debt to EBITDA | 0.24 | 1.54 |
| Profitability Margins | ||
| Gross Profit Margin | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% |
| Net Income Per EBT | 99.79% | 99.43% |
| EBT Per EBIT | 96.04% | 104.66% |
| Return on Assets (ROA) | -68.32% | -36.94% |
| Return on Equity (ROE) | -46.00% | -58.84% |
| Return on Capital Employed (ROCE) | -92.21% | -37.77% |
| Return on Invested Capital (ROIC) | -92.02% | -37.55% |
| Return on Tangible Assets | -144.54% | -64.99% |
| Earnings Yield | -154.53% | -31.32% |
| Efficiency Ratios | ||
| Receivables Turnover | 0.00 | 0.00 |
| Payables Turnover | 0.06 | 0.05 |
| Inventory Turnover | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 |
| Cash Conversion Cycle | -6490.96 | -7169.21 |
| Days of Sales Outstanding | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 |
| Days of Payables Outstanding | 6490.96 | 7169.21 |
| Operating Cycle | 0.00 | 0.00 |
| Cash Flow Ratios | ||
| Operating Cash Flow Per Share | -3.02 | -4.22 |
| Free Cash Flow Per Share | -3.02 | -4.25 |
| Dividend Paid and CapEx Coverage Ratio | -1581.87 | -149.94 |
| Capital Expenditure Coverage Ratio | -1581.87 | -149.94 |
| Operating Cash Flow Coverage Ratio | -2.05 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 |
| Free Cash Flow Yield | -130.12% | -25.62% |
| Valuation Ratios | ||
| Price-to-Earnings (P/E) Ratio | -0.65 | -3.19 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.30 | 1.88 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.77 | -3.90 |
| Price-to-Operating Cash Flow Ratio | -0.77 | -3.93 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | 0.06 |
| Enterprise Value Multiple | -0.38 | -1.79 |
| Enterprise Value | 29.04M | 86.94M |
| EV to EBITDA | -0.38 | -1.79 |
| EV to Sales | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.47 | -2.10 |
| EV to Operating Cash Flow | -0.47 | -2.12 |
| Tangible Book Value Per Share | -1.47 | 3.30 |
| Shareholders’ Equity Per Share | 7.79 | 8.82 |
| Tax and Other Ratios | ||
| Effective Tax Rate | 0.00 | 0.01 |
| Revenue Per Share | 0.00 | 0.00 |
| Net Income Per Share | -3.59 | -5.19 |
| Tax Burden | 1.00 | 0.99 |
| Interest Burden | 0.96 | 1.05 |
| Research & Development to Revenue | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 |
| Income Quality | 0.84 | 0.81 |
Currency in USD